Exciting News for Dystrophic Epidermolysis Bullosa Patients! Major Milestone Approaches!
Krystal Biotech, a prominent player in the biotech sphere, has shared significant updates regarding their investigational treatment, B-VEC, aimed at tackling dystrophic epidermolysis bullosa (DEB). Recently, the European Medicines Agency…